BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA
The invention relates to a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3ε (CD3) together with an immunotherapeutic drug for combined use in treating multiple myeloma.
1 .- 10 . (canceled)
11 . A method of treating multiple myeloma comprising administering to a patient in need of such treatment a therapeutically effective amount of
a) a bispecific antibody comprising a first binding part specifically binding to human B cell maturation antigen (BCMA) and a second binding part specifically binding to human CDR (CD3), wherein said first binding part comprises: a VH region comprising a CDR1H region of SEQ ID NO:21, a CDR2H region of SEQ ID NO:22 and a CDR3H region of SEQ ID NO:17 and a VL region comprising a CDR1L region of SEQ ID NO:27, a CDR2L region of SEQ ID NO:28 and a CDR3L region of SEQ ID NO:20; and,
b) an immunotherapeutic drug selected from the group consisting of thalidomide or an immunotherapeutic derivative thereof, an anti-CD38 antibody, an anti-PD-1 antibody and an anti-PD-L1 antibody;
wherein the bispecific antibody and the immunotherapeutic drug are administered separately or together.
12 . The method according to claim 11 wherein the immunotherapeutic drug is selected from the group consisting of daratumumab, isatuximab, MOR202, Ab79, Ab19, thalidomide, lenalidomide, pomalidomide, CC-122, CC-220, pembrolizumab, pidilizumab, nivolumab, MEDI-0680, PDR001, REGN2810, lambrolizumab, MDX-1106, BGB-108, h409A11, h409A16, h409A17, atezolizumab, avelumab, durvalumab, and MDX-1105.
13 . The method according to claim 12 wherein the immunotherapeutic drug is daratumumab.
14 . The method according to claim 12 wherein the immunotherapeutic drug is isatuximab.
15 . The method according to claim 12 wherein the immunotherapeutic drug is MOR202.
16 . The method according to claim 12 wherein the immunotherapeutic drug is Ab79.
17 . The method according to claim 12 wherein the immunotherapeutic drug is Ab19.
18 . The method according to claim 12 wherein the immunotherapeutic drug is thalidomide.
19 . The method according to claim 12 wherein the immunotherapeutic drug is lenalidomide.
20 . The method according to claim 12 wherein the immunotherapeutic drug is pomalidomide.
21 . The method according to claim 12 wherein the immunotherapeutic drug is CC-122.
22 . The method according to claim 12 wherein the immunotherapeutic drug is CC-220.
23 . The method according to claim 12 wherein the immunotherapeutic drug is pembrolizumab.
24 . The method according to claim 12 wherein the immunotherapeutic drug is pidilizumab.
25 . The method according to claim 12 wherein the immunotherapeutic drug is nivolumab.
26 . The method according to claim 12 wherein the immunotherapeutic drug is MEDI-0680.
27 . The method according to claim 12 wherein the immunotherapeutic drug is PDR001.
28 . The method according to claim 12 wherein the immunotherapeutic drug is REGN2810.
29 . The method according to claim 12 wherein the immunotherapeutic drug is lambrolizumab.
30 . The method according to claim 12 wherein the immunotherapeutic drug is MDX-1106.
31 . The method according to claim 12 wherein the immunotherapeutic drug is BGB-108.
32 . The method according to claim 12 wherein the immunotherapeutic drug is h409A11.
33 . The method according to claim 12 wherein the immunotherapeutic drug is h409A16.
34 . The method according to claim 12 wherein the immunotherapeutic drug is h409A17.
35 . The method according to claim 12 wherein the immunotherapeutic drug is atezolizumab.
36 . The method according to claim 12 wherein the immunotherapeutic drug is avelumab.
37 . The method according to claim 12 wherein the immunotherapeutic drug is durvalumab.
38 . The method according to claim 12 wherein the immunotherapeutic drug is MDX-1105.